Search Results - A. Kaempf
- Showing 1 - 2 results of 2
-
1
Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance by I. Khan, A. Kaempf, S. Raghuwanshi, M. Chesnokov, X. Zhang, Z. Wang, A. Domling, J. W. Tyner, C. Camacho, A. L. Gartel
Published in Blood Cancer Journal (2023-08-01)Get full text
Article -
2
P392: PHARMACOLOGICAL INHIBITION OF SYK CONFERS ANTI-PROLIFERATIVE AND NOVEL ANTI-TUMOR IMMUNE RESPONSES IN AML by L. A. Carvajal, B. Robinson, Y. Kosaka, T. Jacob, J. Lee, T. Hood, K. Baker, A. Kaempf, S. N.-A. Amara, J. Pucilowska, E. Lind, C. Tognon, J. Tyner, P. Kumar, T. Vu, J. DiMartino
Published in HemaSphere (2022-06-01)Get full text
Article
